查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1584105

艰难梭菌感染治疗市场，按产品类型、给药途径、配销通路、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Clostridioides Difficile Infection Treatment Market, By Product Type, By Route of Administration, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 316 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年，艰难梭菌感染治疗市场规模为8,1021万美元，2024年至2032年复合年增长率为6.10%。

艰难梭菌感染治疗市场-市场动态

感染流行率不断上升，新的治疗方法不断开发，以推动市场需求

在感染盛行率上升和新型治疗方法不断开发的推动下，艰难梭菌感染治疗市场正在经历巨大变革。艰难梭菌感染通常与医疗保健环境和抗生素使用有关，对全球医疗保健系统造成沉重负担，凸显了对先进有效治疗方案的需求。有几个因素影响市场动态，这些感染发生率的增加是一个主要的医疗保健挑战。住院时间延长、广谱抗生素的广泛使用以及人口老化增加了个体对艰难梭菌感染的易感性，从而对创新和有效治疗的需求不断增长。技术进步正在重塑治疗格局，抗菌药物、粪便微生物移植 (FMT) 和单株抗体等新型疗法在对抗这些感染方面发挥关键作用。此外，透过基于患者特定感染情况的标靶治疗，精准医学的整合有助于制定更个人化和有效的治疗策略。

艰难梭菌感染治疗市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032）每年将以 6.10% 左右的复合年增长率成长

根据给药途径细分，预计口服药物将在 2023 年显示最大的市场份额

从配销通路细分来看，医院药局是2023年的主导类型

按地区划分，北美是 2023 年的主要收入来源

艰难梭菌感染治疗市场区隔分析：

全球艰难梭菌感染治疗市场根据产品类型、给药途径、配销通路和地区进行细分。

根据给药途径，市场分为两类：口服药物和注射药物。到 2023 年，口服途径仍然是最常见的途径，因为它对患者来说很方便且容易获得。口服抗生素，如甲硝唑、万古霉素和非达霉素，可支持门诊治疗并提高患者的依从性，特别是在较不严重的病例中。然而，在严重或复杂的情况下，可使用注射抗生素製剂。

根据配销通路，市场分为三类：医院药房、零售药房和邮购药房。医院药房预计将在 2023 年占据市场主导地位。作为这些感染的主要治疗中心，医院是治疗药物分配和管理的中心。

艰难梭菌感染治疗市场 - 地理洞察

这个市场超越了地理界限，在北美、拉丁美洲、欧洲、亚太地区、中东和非洲都有业务。预计在预测期内，北美将主导艰难梭菌感染治疗市场，原因是该地区到 2024 年将占据巨大的市场份额，并且市场参与者将重点放在引入新疗法的研发活动上。例如，2022 年 9 月，生物技术公司 Seres Therapeutics, Inc. 宣布完成向美国食品和药物管理局 (FDA) 提交 SER-109 的滚动生物製剂许可申请 (BLA)，旨在预防梭状芽胞桿菌復发艰难梭菌感染。 SER-109 在美国市场的推出预计将有助于巩固这一主导地位。

艰难梭菌感染治疗市场-竞争格局：

CDI 治疗市场中的公司製定了各种策略来建立和扩大其影响力。主要重点放在研究和开发上，以创造创新疗法，特别是对于标准抗生素可能无效的复发性 CDI。与医疗保健提供者和机构的合作对于进行临床试验和收集真实资料以证明产品功效至关重要。行销工作的重点是向医疗保健专业人员提供有关最新治疗方案和指南的教育。此外，公司经常与付款人建立策略伙伴关係，以确保新疗法的报销，改善患者的可及性，同时有效应对监管挑战。

最新进展：

2022 年 10 月，领先的生物产品类型公司 Acurx Pharmaceuticals, Inc. 在美国传染病学会 (IDSA) IDWeek 2022 会议上展示了海报和口头报告，为传染病领域做出了显着贡献。

目录

第 1 章：艰难梭菌感染治疗市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 艰难梭菌感染治疗市场片段（依产品类型）
    • 艰难梭菌感染治疗市场片段（依给药途径）
    • 艰难梭菌感染治疗市场片段（依配销通路）
    • 艰难梭菌感染治疗市场片段（依国家/地区）
    • 艰难梭菌感染治疗市场片段（按地区）
  • 竞争洞察

第 3 章：艰难梭菌感染治疗主要市场趋势

  • 艰难梭菌感染治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 艰难梭菌感染治疗市场限制
    • 市场限制影响分析
  • 艰难梭菌感染治疗市场机会
  • 艰难梭菌感染治疗市场未来趋势

第 4 章：艰难梭菌感染治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：艰难梭菌感染治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：艰难梭菌感染治疗市场格局

  • 2023 年艰难梭菌感染治疗市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：艰难梭菌感染治疗市场 - 依产品类型

  • 概述
    • 按产品类型分類的细分市场占有率分析
    • 甲硝唑
    • 万古霉素
    • 非达霉素

第 8 章：艰难梭菌感染治疗市场 - 依给药途径

  • 概述
    • 按给药途径分類的细分市占率分析
    • 口服
    • 注射剂

第 9 章：艰难梭菌感染治疗市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 邮购药房

第 10 章：艰难梭菌感染治疗市场 - 依地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美艰难梭菌感染治疗主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按产品类型）
    • 北美市场规模与预测（按管理途径）
    • 北美市场规模和预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲艰难梭菌感染治疗主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按产品类型）
    • 欧洲市场规模与预测（按管理途径）
    • 欧洲市场规模和预测（按配销通路）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区艰难梭菌感染治疗主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（依产品类型）
    • 亚太地区市场规模与预测（依管理途径）
    • 亚太地区市场规模和预测（按配销通路）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲艰难梭菌感染治疗主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按产品类型）
    • 拉丁美洲市场规模与预测（按管理途径）
    • 拉丁美洲市场规模和预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲艰难梭菌感染治疗主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按产品类型）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 艰难梭菌感染治疗产业

  • 竞争仪表板
  • 公司简介
    • Novartis
    • Mylan NV
    • Akorn
    • Teva Pharmaceutical Industries Ltd.
    • AstraZeneca
    • Apotex Inc.
    • AbbVie Inc.
    • Pfizer Inc.
    • Strides Pharma Science Limited
    • Sanofi
    • Ferring Pharmaceuticals
    • Sun Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.
    • B. Braun Medical Inc.
    • Eli Lilly and Company
    • Actelion Pharmaceuticals Ltd.
    • Astellas Pharma
    • Perrigo Pharmaceutical.
    • Hikma Pharmaceutical PLC
    • Fresenius Kabi USA
    • Others

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4055

REPORT HIGHLIGHT

Clostridioides Difficile Infection Treatment Market size was valued at USD 810.21 Million in 2023, expanding at a CAGR of 6.10% from 2024 to 2032.

Clostridioides difficile infection (CDI) is a serious gastrointestinal condition caused by the bacterium C. difficile, often triggered by antibiotic use that disrupts the normal gut microbiome. Treatment usually involves targeted antibiotics such as fidaxomicin or vancomycin. For recurrent infections, fecal microbiota transplantation (FMT) is an emerging option that restores healthy gut bacteria. The choice of treatment depends on the patient history, infection's severity, and the likelihood of recurrence. Prompt and appropriate management is important to prevent complications and minimize the risk of transmission in healthcare environments.

Clostridioides Difficile Infection Treatment Market- Market Dynamics

Increasing prevalence of infections and ongoing development of novel treatment methods to propel market demand

The Clostridium difficile infection treatment market is undergoing drastic transformation, driven by the rising prevalence of infections and ongoing development of novel treatment methods. Frequently associated with the healthcare settings and antibiotic use, Clostridium difficile infections pose a substantial burden on global healthcare systems, highlighting a need for an advanced and effective treatment options. Several factors influence market dynamics, with the increasing incidence of these infections being a major healthcare challenge. Prolonged hospital stays, widespread use of broad-spectrum antibiotics, and an aging population have heightened individual susceptibility to Clostridium difficile infections, creating a growing demand for innovative and effective treatments. Technological advancements are reshaping the treatment landscape, with novel therapies such as antimicrobial agents, fecal microbiota transplantation (FMT), and monoclonal antibodies playing a key role in combating these infections. Additionally, the integration of precision medicine, through targeted therapies based on a patient's specific infection profile, is contributing to more personalized and effective treatment strategies.

Clostridioides Difficile Infection Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.10% over the forecast period (2024-2032)

Based on Route of Administration segmentation, oral was predicted to show maximum market share in the year 2023

Based on Distribution Channel segmentation, Hospital Pharmacies was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Clostridioides Difficile Infection Treatment Market- Segmentation Analysis:

The Global Clostridioides Difficile Infection Treatment Market is segmented on the basis of Product Type, Route of Administration, Distribution Channel, and Region.

The market is divided into two categories based on Route of Administration: Oral and Injectables. In 2023, the oral route remains the most common due to its convenience and accessibility for patients. Oral administration of antibiotics, such as metronidazole, vancomycin, and fidaxomicin, supports outpatient care and improves patient adherence, particularly in less severe cases. However, in severe or complicated cases, injectable antibiotic formulations are utilized.

The market is divided into three categories based on Distribution Channel: Hospital Pharmacies, Retail Pharmacies and Mail-Order Pharmacies. Hospital pharmacies are expected to dominate the market in 2023. Hospital pharmacies play a key role, particularly given the need for inpatient care in severe cases. As primary treatment centers for these infections, hospitals are central to the distribution and administration of therapeutic agents.

Clostridioides Difficile Infection Treatment Market- Geographical Insights

This market transcends geographical boundaries, with a presence in North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America is projected to dominate the Clostridioides difficile infection treatment market during the forecast period, driven by the region's significant market share in 2024 and the focus of market players on research and development activities to introduce new therapies. For example, in September 2022, Seres Therapeutics, Inc., a biotechnology company, announced the completion of its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for SER-109, aimed at preventing recurrent Clostridioides difficile infection. The introduction of SER-109 in the U.S. market is expected to contribute to this dominance.

Clostridioides Difficile Infection Treatment Market- Competitive Landscape:

Companies in the CDI treatment market devising various strategies to establish and expand their presence. A major emphasis is placed on research and development to create innovative therapies, especially for recurrent CDI, where standard antibiotics may be ineffective. Collaborations with healthcare providers and institutions are crucial for conducting clinical trials and gathering real-world data to demonstrate product efficacy. Marketing efforts focus on educating healthcare professionals about the latest treatment options and guidelines. Additionally, companies often form strategic partnerships with payers to secure reimbursement for new therapies, improving patient access while effectively addressing regulatory challenges.

Recent Developments:

In October 2022, Acurx Pharmaceuticals, Inc., a leading bioProduct Type company, made notable contributions to the field of infectious diseases by presenting both a poster and an oral presentation at the Infectious Disease Society of America (IDSA) IDWeek 2022 Conference.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT

Novartis

Mylan N.V.

Akorn

Teva Pharmaceutical Industries Ltd.

AstraZeneca

Apotex Inc.

AbbVie Inc.

Pfizer Inc.

Strides Pharma Science Limited

Sanofi

Ferring Pharmaceuticals

Sun Pharmaceutical Industries Ltd.

Merck & Co., Inc.

B. Braun Medical Inc.

Eli Lilly and Company

Actelion Pharmaceuticals Ltd.

Astellas Pharma

Perrigo Pharmaceutical.

Hikma Pharmaceutical PLC

Fresenius Kabi USA

Others

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET, BY PRODUCT TYPE - MARKET ANALYSIS, 2019 - 2032

  • Metronidazole
  • Vancomycin
  • Fidaxomicin

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectables

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail-Order Pharmacies

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Clostridioides Difficile Infection Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Clostridioides Difficile Infection Treatment Market Snippet by Product Type
    • 2.1.2. Clostridioides Difficile Infection Treatment Market Snippet by Route of Administration
    • 2.1.3. Clostridioides Difficile Infection Treatment Market Snippet by Distribution Channel
    • 2.1.4. Clostridioides Difficile Infection Treatment Market Snippet by Country
    • 2.1.5. Clostridioides Difficile Infection Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Clostridioides Difficile Infection Treatment Key Market Trends

  • 3.1. Clostridioides Difficile Infection Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Clostridioides Difficile Infection Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Clostridioides Difficile Infection Treatment Market Opportunities
  • 3.4. Clostridioides Difficile Infection Treatment Market Future Trends

4. Clostridioides Difficile Infection Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Clostridioides Difficile Infection Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Clostridioides Difficile Infection Treatment Market Landscape

  • 6.1. Clostridioides Difficile Infection Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Clostridioides Difficile Infection Treatment Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2023 & 2032 (%)
    • 7.1.2. Metronidazole
    • 7.1.3. Vancomycin
    • 7.1.4. Fidaxomicin

8. Clostridioides Difficile Infection Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Injectables

9. Clostridioides Difficile Infection Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Mail-Order Pharmacies

10. Clostridioides Difficile Infection Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Clostridioides Difficile Infection Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Clostridioides Difficile Infection Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Clostridioides Difficile Infection Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Clostridioides Difficile Infection Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Clostridioides Difficile Infection Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Clostridioides Difficile Infection Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Novartis
    • 11.2.2. Mylan N.V.
    • 11.2.3. Akorn
    • 11.2.4. Teva Pharmaceutical Industries Ltd.
    • 11.2.5. AstraZeneca
    • 11.2.6. Apotex Inc.
    • 11.2.7. AbbVie Inc.
    • 11.2.8. Pfizer Inc.
    • 11.2.9. Strides Pharma Science Limited
    • 11.2.10. Sanofi
    • 11.2.11. Ferring Pharmaceuticals
    • 11.2.12. Sun Pharmaceutical Industries Ltd.
    • 11.2.13. Merck & Co., Inc.
    • 11.2.14. B. Braun Medical Inc.
    • 11.2.15. Eli Lilly and Company
    • 11.2.16. Actelion Pharmaceuticals Ltd.
    • 11.2.17. Astellas Pharma
    • 11.2.18. Perrigo Pharmaceutical.
    • 11.2.19. Hikma Pharmaceutical PLC
    • 11.2.20. Fresenius Kabi USA
    • 11.2.21. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us